The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
暂无分享,去创建一个
[1] B. Seliger,et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.
[2] B. Seliger,et al. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. , 2003, Trends in immunology.
[3] M. Weller,et al. A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.
[4] S. Ugurel,et al. HLA-G in Melanoma: A New Strategy to Escape from Immunosurveillance? , 2002, Oncology Research and Treatment.
[5] T. Ratliff,et al. Immunotherapy of urologic tumors: principles and progress. , 2002, Urologic oncology.
[6] R. Dummer,et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. , 2002, Blood.
[7] R. Dummer,et al. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. , 2001, The Journal of investigative dermatology.
[8] S. Chouaib,et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. , 2001, Cancer research.
[9] M. Kurrer,et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. , 2001, The American journal of pathology.
[10] P. Selby,et al. Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule , 2001, Cancer Immunology, Immunotherapy.
[11] J. Dausset,et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. , 2001, Transplantation proceedings.
[12] J. Dausset,et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. , 2001, International immunology.
[13] A. Moretta,et al. Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. , 2000, Human immunology.
[14] N. Rouas-Freiss,et al. HLA-G and HLA-E: fundamental and Pathophysiological aspects. , 2000, Immunology today.
[15] G. Ferrara,et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. , 2000, Human immunology.
[16] B. Seliger,et al. Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.
[17] S. Wagner,et al. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma , 2000, The Lancet.
[18] A. Toubert,et al. Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD81 , 2000, The Journal of Immunology.
[19] N. Won,et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. , 2000, Archives of pathology & laboratory medicine.
[20] M. Probst-Kepper,et al. A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.
[21] Seliger,et al. Gene Transfer of the Co‐Stimulatory Molecules B7‐1 and B7‐2 Enhances the Immunogenicity of Human Renal Cell Carcinoma to a Different Extent , 1999, Scandinavian journal of immunology.
[22] J. Dausset,et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. , 1999, International immunology.
[23] F. Garrido,et al. Expression of HLA G in human tumors is not a frequent event , 1999, International journal of cancer.
[24] N. Bander,et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] J. Dausset,et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. , 1999, Cancer research.
[26] B. Drénou,et al. HLA-G protein expression is not induced during malignant transformation. , 1999, Tissue antigens.
[27] B. Seliger,et al. Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer , 1999, International journal of cancer.
[28] R. Figlin. Renal cell carcinoma: management of advanced disease. , 1999, The Journal of urology.
[29] G. Köhler,et al. Pro-Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma , 1999, European Urology.
[30] G. T. Budd,et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] D. Schendel,et al. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. , 1998, Cancer research.
[32] B. Seliger,et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] R. Tampé,et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. , 1996, Cancer research.
[34] E. Halapi,et al. Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinoma , 1995, International journal of cancer.
[35] D. Petrylak,et al. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.
[36] B. Seliger,et al. Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones , 1994, International journal of cancer.
[37] E. Klein,et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[38] D. Longo,et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.
[39] C. Cordon-Cardo,et al. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. , 1991, Cancer research.
[40] S. Kagawa,et al. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. , 2001, Molecular urology.
[41] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[42] Taylor Murray,et al. Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.